학술논문

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
Document Type
Journal
Source
CLINICAL CANCER RESEARCH; MAY 1 2023, 29 9, p1651-p1657, 7p.
Subject
Language
English
ISSN
15573265